That's fair enough, although I have a different view. I posted elsewhere on this forum some time ago I believe we have seen the bottom(s) for biotech in May and June and any weakness now presents a good medium to long term buying opportunity. Each to their own though!
I also wouldn't be trying to draw any conclusions from the TransMolecular 131-I TM-601 trial. Radiotherapy and cell therapy are obviously completely different therapeutic modalities and, although they share the same target in this instance, I don't believe you can extrapolate anything meaningful from one to the other - not without a lot more data anyway.
In any event, your final conclusion is probably right in that at $40m market cap there is at least 10 fold upside on further positive results so there should be opportunity to get in for the ride if you know what you're looking at. Just won't compound the same returns!
(20min delay)